Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
3.880
+0.240 (6.59%)
At close: Nov 6, 2026, 4:00 PM EST
3.830
-0.050 (-1.29%)
After-hours: Nov 6, 2026, 7:55 PM EST
Company Description
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States.
Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Nevan Elam |
Contact Details
Address: 275 Shoreline Drive, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650 206 4507 |
| Website | rezolutebio.com |
Stock Details
| Ticker Symbol | RZLT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001509261 |
| CUSIP Number | 76200L309 |
| ISIN Number | US76200L3096 |
| Employer ID | 27-3440894 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nevan Charles Elam J.D. | Founder, Chief Executive Officer and Acting Chairman of the Board |
| Daron G. Evans M.B.A., M.S. | Chief Financial and Business Officer |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer |
| Michael R. Deperro | Senior Vice President and Head of Operations |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific and Patient Affairs |
| Melissa Quinn | Senior Director of People and Culture |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 5, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 5, 2026 | 10-Q | Quarterly Report |
| Nov 5, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 28, 2026 | SCHEDULE 13G | Filing |
| Oct 21, 2026 | DEF 14A | Other definitive proxy statements |
| Oct 15, 2026 | DRS | [Cover] Draft Registration Statement |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 7, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 5, 2026 | 8-K | Current Report |